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and to 50mg in 3% of pts. The reasons for dose reduction were mainly 
rash 54%, diarrhea 19.4%, pruritus 9.7%; rash and diarrhea 6.5%. 
Conclusions: Based on a large number of unselected pts with advanced 
NSCLC in Israel, the safety data obtained from the interim results 
with erlotinib conﬁrm the favorable safety proﬁle of erlotinib previ-
ously observed in clinical trials. To date, the results show erlotinib 
to be generally well tolerated, thus allowing most pts to receive the 
recommended daily dose of 150mg. Efﬁcacy data may be available by 
September 2007.
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Background: The addition of bevacizumab (B) to chemotherapy 
improves survival in patients (pts) with previously untreated metastatic 
NSCLC. The addition of bevacizumab to erlotinib (E) appears promis-
ing in second line therapy of NSCLC. Bevacizumab plus erlotinib 
(B+E) has never been tested in 1st line NSCLC. 
Methods: Eligible pts with previously untreated stage IIIB (pleural 
effusion) or stage IV NSCLC and normal organ function without 
hemoptysis or brain metastasis were treated with B (15mg/kg every 21 
days) plus E (150mg once daily) for 4 cycles (cycle- 21 days) followed 
by B (15mg/kg), carboplatin (AUC 6) and paclitaxel (200 mg/m2) every 
21 days for 4 cycles. Pts who did not progress on initial B+E received 
maintenance therapy with B+E until progression.
Results: We have enrolled 40 pts (of 48 planned) in this ongoing study. 
The characteristics: 25 male, 15 female; median age 70 years; 37 stage 
IV, 3 stage IIIB; 3 never smokers; 26 adenocarcinoma, 10 non-small 
cell lung cancer not otherwise speciﬁed, 3 undifferentiated carcinoma, 
1 adenocarcinoma with BAC; performance status 0 in 16 and 1 in 
24. Twenty three pts have completed 4 cycles of B+E with 5 partial 
responses (22%), 13 stable disease (56%) and 5 progressive disease 
(22%). Sixteen pts have completed bevacizumab plus chemotherapy 
with best responses of 5 partial response (31%), 9 stable disease (56%), 
2 progressive disease (12%). Of the 11 pts treated with maintenance 
B+E, 4 developed progressive disease and have discontinued therapy. 
The median number of cycles received during maintenance therapy 
with B+E was 6 (range 2-15+). Treatment related toxicities: related to 
B+E- grade 3 rash (3 pts), grade 3 fatigue (2 pts), and grade 3 epistaxis 
(1 pt); related to B and chemotherapy- grade 3 neuropathy (2 pts), 
grade 3 hypersensitivity reaction (1 pt), grade 4 neutropenia (2 pts), 
and grade 4 arterial thrombosis (1 pt). Most notably, there have been no 
major bleeding episodes so far. 
Conclusions: 1. The combination of B+E achieved a disease control 
rate of 78% in previously untreated patients with IIIB/IV NSCLC and 
is well tolerated. 2. The initial administration of 4 cycles of B+E does 
not impair the efﬁcacy platinum based doublet chemotherapy with 
bevacizumab.
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Background: The epidermal growth factor receptor (EGFR) is ex-
pressed in many human epithelial malignancies, including NSCLC. The 
response rates to EGFR tyrosine kinase inhibitors (TKIs) in unselected 
NSCLC patients rages from 9-27%. NSCLC cell lines highly sensitive 
to EGFR TKIs express E-cadherin. Patients with high E-cadherin ex-
pression in tumors samples have improved time-to-progression (TTP) 
after treatment with EGFR TKI erlotinib, indicating the signiﬁcant role 
of epithelial-mesenchymal transition (EMT) to predict sensitivity/re-
sistance to EGFR inhibitors. These results suggest that high E-cadherin 
expression would be a clinically relevant biomarker for patient’s selec-
tion to EGFR TKI therapy. The aim of the present study was to investi-
gate the potential association between serum E-cadherin expression and 
clinical activity of geﬁtinib in European NSCLC patients. 
Methods and Results: Serum E-cadherin levels were evaluated by 
ELISA using commercially available kit (R&D Systems). Statistical 
evaluation was performed by Kaplan-Meier analysis and a Cox pro-
portional hazard model. Among 135 consecutive patients treated with 
geﬁtinib (median age, 67 years; 75% males; 83% ever smokers), 123 
were evaluable for response, TTP and overall survival (OS). Forty-four 
(36%) had stable disease (SD) and 15 (13%) had objective response 
(OR). Serum E-cadherin levels ranged from 15 to 203 ng/mL with a 
median value of 30 ng/mL. The whole population was divided into two 
groups based on median E-cadherin levels (< 30 versus ≥ 30 ng/mL). 
Higher serum E-cadherin level was observed in patients with older age 
(P=.003), ECOG PS of 2 versus 0 or 1 (P=.027), and squamous cell 
histology (P=.045).
The response rates were 13% and 11% in patients with low and high 
E-cadherin level, respectively (P=.809); disease control rates were 52% 
and 44% respectively (P=.415). Median TTP and OS were 3.5 and 5.8 
months, and 3 and 7 months, in patients with low and high E-cadherin 
levels (P=.245; P=.434 respectively). 
Conclusions: These results indicate that higher E-cadherin levels are 
associated with age, advanced PS and squamous cell histology. Serum 
E-cadherin does not appear to predict response, TTP, and OS in patients 
with NSCLC after therapy with geﬁtinib. Corresponding E-cadherin 
tissue studies are ongoing.
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Background: Two case reports describe a response to E after failure of 
G (Garﬁeld DH, J Clin Oncol 2005) or to G after failure of E (Choong 
NW et al, Nat Clin Pract Oncol 2006) in patients (pts) with advanced 
NSCLC. Otherwise, a limited experience in 5 pts suggests that E is not 
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effective in pts progressing on G (Viswanathan A et al, Lung Cancer 
2005). Aim of this study was the evaluation of response and time to 
progression (TTP) in advanced NSCLC pts treated with G after failure 
of E.
Methods: Pts received G 250 mg/day after disease progression (PD) 
with E 150 mg/day. Pts accrual was stopped on August 2006 after the 
approval of E for use in Italy and the consequent closure of the G com-
passionate-use program. 
Results: From May 2005 to August 2006, 15 pts were enrolled. Median 
age 65 years (50-85); males= 14 pts (93%); never/former smokers= 
4/10 pts (26/67%); adenocarcinoma= 10 pts (67%); PS 0/1= 5/10 pts 
(33/67%); in 2 pts (13%) E was administered as ﬁrst-line therapy, 8 pts 
(53%) received 2 prior lines of chemotherapy (CT) and 3 pts (20%) 
received CT between E and G. One patient (7%) had a partial response 
(PR) and 5 pts (33%) had disease stabilization (SD) with E; with G no 
PR and 6 SD (40%) were obtained. Five out of 6 RP/SD pts with E, had 
SD with G; 8 out of 9 PD pts with E, had PD with G; 1 SD patient with 
E, progressed with G and 1 vice versa. TTP in RP/SD pts was 7.2 and 
3.4 months for E and G respectively; in PD pts TTP was 1.7 and 1.6 for 
E and G respectively.
Conclusions: Our data suggest that there is a beneﬁt with G in pts who 
had RP/SD with E and that is associated with a good TTP. Conversely 
G is not recommended in pts that immediately progressed after E. An 
analysis of the role of mutational status and other biomarkers in pre-
dicting clinical outcome is currently underway.
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Background: One retrospective study (Hotta K, Ann Oncol 2005), in-
vestigating the prognosis of patients (pts) obtaining SD as best response 
with G treatment, has demonstrated that both progression-free survival 
(PFS) and survival (S) were signiﬁcantly longer than those in pts with 
progressive disease (PD). The aim of this retrospective study was to 
compare the PFS and S outcome in pts with advanced NSCLC who 
achieved SD or partial response (PR) after treatment with E or G.
Methods: Pooled data from 62 pts, entered into an expanded access 
program of E (n=31) and a compassionate-use program of G (n=31), 
were retrospectively analyzed. E and G were given orally at 150 and 
250 mg per day respectively and were continued until disease progres-
sion, development of unacceptable toxicity or patient’s refusal.
Results: Pts characteristics: median age 69 years (42-85); females= 
21 pts (34%); never/former smokers= 16/38 pts (26/61%); adenocar-
cinoma/BAC= 35/10 pts (56/16%); PS 0/1= 18/38 pts (29/61%). In 16 
pts (26%) E or G were given as ﬁrst-line therapy; 21 pts (34%) had 
received ≥2 prior lines of chemotherapy. Six pts (10%) achieved a PR 
and 18 pts (29%) obtained SD. TTP and OS in pts obtaining PR and 
SD were comparable: 7 vs 5.5 and 9.7 vs 9.1 months respectively. In 
progressing pts median TTP and OS were 1.7 and 3.7 months. No dif-
ference in response, TTP and S between E and G were demonstrated.
Conclusions: Our ﬁndings indicate the importance of achieving disease 
control with both E and G treatment. Pts obtaining SD with E or G had 
a similar PFS and S compared with those having PR. 
An analysis of the role of mutational status and other biomarkers in 
predicting clinical outcome is currently underway.
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Background: BIBF 1120 is a highly potent, orally bioavailable triple 
angiokinase inhibitor (VEGFRs, PDGRs, FGFRs) that suppresses tu-
mor growth through mechanisms inhibiting tumor neovascularization. 
Pemetrexed is an antifolate agent that inhibits de novo DNA synthesis 
pathways and has demonstrated clinical beneﬁt in advanced or meta-
static NSCLC after prior ﬁrst line chemotherapy. 
This Phase I, open-label dose escalation study investigated the combi-
nation of BIBF 1120 together with pemetrexed in previously treated pa-
tients with recurrent advanced stage NSCLC. The potential additive or 
synergistic effects of novel therapeutic regimens may make combina-
tions of these agents particularly attractive for the treatment of patients 
with recurrent NSCLC compared to a single agent alone.
The primary objectives of this trial were to determine the safety, toler-
ability, and maximum tolerated dose (MTD) of BIBF 1120 in combina-
tion with pemetrexed.
Methods: Patients with advanced stage NSCLC, PS 0-1, previously 
treated with one ﬁrst line platinum-based chemotherapy regimen were 
eligible for this trial. The trial was an open label, dose escalation design 
with BIBF 1120 at a starting dose of 100 mg bid, taken on days 2-21, 
combined with standard dose pemetrexed (500 mg/m2) given as a 10 
minute intravenous infusion on day 1 of a 21 day cycle. Patients could 
be treated for a minimum of four and a maximum of six cycles of 
the combination therapy, with an option of BIBF 1120 monotherapy 
following the completion of the combination stage. BIBF 1120 was 
escalated at doses of 50 mg per cohort until the MTD dose was deter-
mined. The MTD was deﬁned as the dose of BIBF 1120 which was one 
dose cohort below the dose at which two or more out of six patients 
experienced dose limiting toxicity (DLT) in the ﬁrst treatment cycle. 
Tumor assessments were performed at screening and after every second 
treatment cycle according to RECIST.
Results: Twenty-six patients (13 male, 13 female) in total and 12 at 
the MTD were treated in this study. The MTD dose of BIBF 1120 was 
determined to be 200 mg bid in combination with standard dose peme-
trexed. Generally the combination of BIBF 1120 and pemetrexed was 
well tolerated. A total of 17 DLT events (CTCAE Grade 3) occurred 
in the ﬁrst treatment cycle for all doses, including elevations in liver 
enzymes (3/17), fatigue (4/17), anorexia (2/17) and gastrointestinal 
disorders (6/17). These events resolved following discontinuation of 
the study medication. No Grade 4 events occurred in the study. Best 
responses by RECIST included (20 evaluable for response) 1 complete 
